Clinical Trials Browser

Phase 2 × NIH × LMB-100 × Clear all

NCT04027946 2024-04-16

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

6 enrolled 14 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03644550 2021-12-02

Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma

Phase 2 Terminated

18 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma